Quetiapine XR in Schizophrenic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01071135
Recruitment Status : Terminated (Planned number of 30 subjects could not be recruited during recruitment phase.)
First Posted : February 19, 2010
Last Update Posted : November 11, 2011
Hannover Clinical Trial Center GmbH
Information provided by (Responsible Party):
Wolfgang Dillo, Hannover Medical School

February 18, 2010
February 19, 2010
November 11, 2011
September 2009
August 2010   (Final data collection date for primary outcome measure)
Reduction in PANSS total score [ Time Frame: within 3 months ]
The primary variable will be the proportion of patients with a 30% reduction from screening visit to month 3 in PANSS total score.
Not Provided
Complete list of historical versions of study NCT01071135 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Quetiapine XR in Schizophrenic Patients
Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study-
The purpose of the study is to determine the effect of Quetiapine in patients with schizophrenia induced by cannabis abuse.
To evaluate the effect of quetiapine on positive and negative symptoms of schizophrenia on schizophrenic patients associated with cannabis abuse and patients with psychotic disorders through cannabis abuse.
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: Quetiapine XR
Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
Experimental: Quetiapine XR
Intervention: Drug: Quetiapine XR
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
August 2010
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Females and/or males aged 18 to 60 years.
  2. Provision of written informed consent. In case of acute psychosis written informed consent has to be obtained from the legal representative of the patient, if applicable or from two independent physicians not involved in the study. When the patient recovers, the written informed consent has to be signed by the patient itself.
  3. A diagnosis of schizophrenia (ICD10: F20.0, F20.1, F20.2, F20.4, F20.5) with associated cannabis abuse and/or psychotic disorders (e.g. schizophrenia) through cannabis (ICD 10: F12.5, F12.7).
  4. A score of at least 15 on the positive scale of the PANSS.
  5. Female patients of childbearing potential must be using a reliable method of contraception (i.e. contraceptive pill, contraceptive coil, sterilization, hysterectomy) and have a negative blood human chorionic gonadotropin (HCG) test at enrollment.
  6. Able to understand and comply with the requirements of the study. In case of acute psychosis only those patients are included that are expected to understand the requirements under healthy conditions.

Exclusion Criteria:

  1. Pregnancy or lactation.
  2. Any ICD10 F-criteria not defined in the inclusion criteria.
  3. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to themselves or others.
  4. Known intolerance or lack of response to quetiapine fumarate as judged by the investigator.
  5. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment, including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir.
  6. Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids.
  7. Patients who require treatment with one or more additional neuroleptics to quetiapine.
  8. Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation.
  9. Substance or alcohol dependence within 4 weeks prior to enrolment, at enrollment and during the study (except for cannabis, caffeine or nicotine dependence), as defined by DSM-IV criteria.
  10. Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment.
  11. Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator.
  12. An absolute neutrophil count (ANC) of ≤ 1.5 x 109 per liter.
  13. Involvement in the planning and conduct of the study.
  14. Previous enrollment or randomisation of treatment in the present study.
  15. A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:

    • Unstable DM as defined as enrollment glycosylated haemoglobin (HbA1c) >8.5%.
    • Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.
    • Not under physicians care for DM.
    • Physicians responsible for patient´s DM care has not indicated that patient´s DM is controlled. Physician responsible for patient´s DM care has not approved patient´s participation in the study.
    • Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to inclusion. For thiazolidinediones (glitazones) this period should be at least 8 weeks.
    • Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks.

    Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study.

  16. Previous treatment with study medication within the last 4 weeks prior to enrollment into this study.
  17. Participation in another drug trial within 4 weeks prior enrollment into this study or current participation in another clinical trial.
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Wolfgang Dillo, Hannover Medical School
Hannover Medical School
  • Hannover Clinical Trial Center GmbH
  • AstraZeneca
Principal Investigator: Wolfgang Dillo, MD Hannover Medical School
Hannover Medical School
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP